#NIH clinical trial of investigational vaccine for #COVID_19 begins
![]() A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today. The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine. |

Pompeii home buried by Mount Vesuvius yields personal treasures untouched for nearly 2,000 years
12117:13
SpaceX Catches Starship in the Air After 22 Hours in Orbit — A First in Space History (photo, video)
90716.11.2026, 01:19
‘Once-in-a-lifetime chance’: Japan launches historic mission to collect rocks from Mars’s moon Phobos
96620.10.2026, 22:54
Evidence for funerary behaviour and lethal trauma in a new Neanderthal individual from Shanidar Cave (photo)
109717.10.2026, 00:30
Stone Age sites identified in Uzbekistan’s Jizzakh region
81611.10.2026, 16:24
Nobel physics prize awarded for detection of cosmic neutrinos
102906.10.2026, 19:12
